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Abstract
In developing muscle cells environmental stimuli transmitted by purines binding to the specific receptors are crucial
proliferation regulators. C2C12 myoblasts express numerous purinergic receptors representing both main classes: P2X
and P2Y. Among P2Y receptors we have found the expression of P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 family members
while among P2X receptors P2X4, P2X5 and P2X7 were discovered. We have been able to show that activation of
those receptors is responsible for ERK class kinase activity, responsible for regulation of cell proliferation pathway. We
have also demonstrated that this activity is calcium dependent suggesting Ca2+ ions as secondary messenger between
receptor and kinase regulatory system. More specifically, we do suspect that in C2C12 myoblasts calcium channels of
P2X receptors, particularly P2X5 play the main role in proliferation regulation. In further development of myoblasts into
myotubes, when proliferation is gradually inhibited, the pattern of P2 receptors is changed. This phenomenon is followed
by diminishing of the P2Y2-dependent Ca
2+ signaling, while the mRNA expression of P2Y2 receptor reminds still on the
high level. Moreover, P2X2 receptor mRNA, absent in myoblasts appears in myotubes. These data show that
differentiation of C2C12 cell line satellite myoblasts is accompanied by changes in P2 receptors expression pattern.
Abbreviations: 2MeSADP – 2-methylthio-ADP; BzATP – 30-0(4-benzoyl)benzoyl ATP; [Ca2+]i – intracellular Ca2+ con-
centration; DMEM – Dulbecco’s modified essential medium; ERK – Ras/extracellular signal-regulated kinase; FCS – fetal
calf serum; GAPDH – glycerol 3-phosphate dehydrogenase; HS – horse serum; InsP3 – inositol 1,4,5-trisphosphate; PLC –
phospholipase C; PPADS – pirydoxal-phosphate-6-azophenyl-20, 40-disulphonic acid
Introduction
Skeletal muscle satellite cells are precursors of mammalian
skeletal muscle multinucleated myotubes. The small
population of these satellite cells posses in vivo a special
ability to respond to myofibers damage. After muscle fiber
injury, satellite cells are activated, start to proliferate,
become committed to differentiation and fuse to form new
myotubes [1Y4]. Similar process of myotubes formation
can be observed in vitro using primary culture of satellite
cells [4Y6], or satellite myoblast cell cultures [7].
Differentiation of muscle cells is regulated by extracel-
lular growth factors that transmit signals into the cells [3].
Functional studies on satellite cells have shown that MAPK
activity is involved in directing myogenesis [8Y10].
Extracellular ATP acting trough P2X and P2Y purinergic
receptors is also involved in this process [5, 11Y13].
P2X1Y7 receptors are intrinsic ligand-gated ion channels
and activation of these receptors by ATP evokes a flow of
cations (Na+, K+ and Ca2+) across the plasma membrane.
P2Y receptors are G-protein coupled receptors linked to
activation of phospholipase C (PLC), inositol lipid signal-
ling and the mobilization of intracellular Ca2+ (for re-
view see: [14Y17]). Within the family of P2Y receptors
P2Y1 responds selectively to ADP. 2-methylthio-ADP
(2MeSADP) is also a selective agonist of high potency
for this receptor, while UTP is not effective. In contrast,
P2Y2 receptor responds to ATP and UTP, while 2MeSADP
has no effect on its activation. P2Y4 receptor responds to
UTP, and P2Y6 to UDP. In the case of P2Y12 and P2Y13
receptors responding to ADP, their coupling to Gi protein
results in inhibition of cAMP formation [16, 18Y20].
It is well established that ATP has potent effects on
developing skeletal muscle. These effects are developmen-
tally regulated and those responses have been shown to
be characteristic for activation of the P2X purinergic
receptors [11]. More recently, the expression of specific
P2X receptor subtypes during skeletal muscle develop-
ment [5, 11, 13] and in regenerating skeletal muscles [4]
have been demonstrated. Among these receptors, P2X5 and
P2X6, and P2X2 and P2X5, have been found to be
expressed in chick and rat skeletal muscle development,
respectively [5, 11].
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On the contrary, the expression and function of P2Y
nucleotide receptors in developing skeletal muscle cells has
rarely been studied. In chick muscle, the P2Y1 receptor
was implicated in the regulation of acetylcholine receptor
[21]. The expression of this receptor was detected during
the first 10 days of chick embryonic development [12]. In
rat embryonic skeletal muscle cells, Cheung et al. [22]
found similar early expression of the P2Y1 receptor,
whereas the P2Y2 receptor expression became progressive-
ly stronger with development and the P2Y4 receptor
expression was similarly high at early and late embryonic
days. In contrast, postnatal skeletal muscles from 3-week-
or 2-month-old rats demonstrated the down-regulation of
P2Y4 receptor expression and P2Y1 as well as P2Y2
receptor expression were detected only in the small pop-
ulation of cells present between muscle fibers, tentatively
identified as satellite cells [22].
In this study, using RT-PCR analysis we investigated the
presence of P2Y and P2X receptors on cultured mouse
satellite C2C12 cells and their involvement in ERK1/2
activation and intracellular Ca2+ mobilization. We com-
pared the mRNA expression levels of P2Y1, P2Y2, P2Y4,
P2Y6, P2Y12 and P2X1Y7 receptors in C2C12 myoblasts
and myotubes and demonstrated that in myotubes the
expression of all P2Y receptors mRNA decreased, except
of P2Y2 mRNA. P2X4, P2X5 and P2X7 receptors are
present both in myoblast and myotubes while receptor
P2X2 mRNA appears only in myotubes. We suspect that
nucleotide can regulate myoblast proliferation and dif-
ferentiation via both P2X and P2Y receptors, and partic-
ularly the ATP-responding P2X5 and P2Y2 receptor seem
to be involved in these processes.
Materials and methods
Materials
Dulbecco’s modified essential medium (DMEM), fetal calf
serum (FCS), horse serum (HS) was from Gibco BRL. TRI
reagent, ADP, ATP, UTP, UDP, 2MeSADP, BzATP, BSA,
EGTA, Trypsin-EDTA solution, phosphate-buffered solu-
tion (PBS), ethidium bromide, agarose and common chem-
icals were purchased from Sigma Chemical Co. Penicilin
was from Polfa Tarchomin Poland. Fura-2/AM was from
Molecular Probes, Inc. Pyridoxal-phosphate-6-azophenyl-
20, 40-disulfonic acid (PPADS) was obtained from Research
Biochemicals International. Expand RT enzyme was
purchased from Roche. Taq PCR Core Kit was obtained
from QIAGEN and M-MLV Reverse Transcriptase from
Sigma Chemical Co.
Cell culture
C2C12 cells, a murine myoblast cell line was from the
American Tissue Culture Collection, Rockville, USA,
(ATCC) and was a kind gift from Prof Jerzy Moraczewski,
Warsaw University, Warsaw, Poland. Cells were cultured
in DMEM with high glucose (4500 g dmj3) and Glutamax
I, supplemented with 10% (vvj1) FCS and penicilin (100
UI mlj1) under humidified atmosphere of 5% CO2 at
37 -C. The cells were passaged when reached state of
about 60% confluency, and medium was changed three
times a week. For experiments, cells were cultivated in
DMEM supplemented with 10% FCS to reach 80%
confluence: in 60-mm dishes (for Western blot analysis),
in 100-mm dishes (for RT-PCR analysis), on 24-mm glass
coverslips in 35-mm dishes (for calcium measurement).
Medium was changed 12 h before each experiment. In case
of calcium measurements, 30 min before the experiment,
cells were washed once with PBS and once with the
solution containing: 137 mM NaCl, 2.7 mM KCl, 1-mM
Na2HPO4, 25 mM glucose, 20 mM HEPES (pH 7.4), 1-
mM MgCl2, 1% bovine serum albumin and 2-mM CaCl2
(later referred as standard buffer). Only in experiments
performed in the absence of external Ca2+, 500 mM EGTA
was added instead of 2 mM CaCl2. In case of differetiation
myoblasts to myotubes, cells were grown to 90% conflu-
ency and medium was changed to DMEM supplemented
with 2% HS, which was changed third and fifth day of
culture. Myotubes were harvested for experiments on fifth
and seventh day of differentiation.
Measurement of intracellular calcium
Cells on coverslips were washed once with PBS and once
with the standard buffer. The cells were incubated at 37 -C
for 30 min in the standard buffer with 1 mm Fura-2 AM.
Thereafter, the coverslips were mounted in a chamber over
a Nikon Diaphot inverted-stage microscope equipped with
a fluo  40/1.3 NA oil-immersion objective lens. Fura-2
digital fluorescence microscopy was used to determine the
changes in intracellular calcium levels ([Ca2+]i) [23]. Ludl
Lep MAC 5000 filter wheel system loaded with Chroma
Inc. Fura-2 filter set was used for illumination of speci-
mens. Images were acquired using Retiga 1300 chilled
digital CCD camera (QImaging Inc.). Data processing was
carried out using AQM Advance 6 (Kinetic Imaging Inc)
and MS Excel software.
Preparation of cell extracts and Western blot analysis of
phospho-ERK1 and ERK2
For these experiments cells were plated in 60-mm dishes
and were incubated with agonists in DMEM medium
at 37 -C for various times. When antagonists were used,
they were applied 2 min prior to the addition of agonists.
The reaction was stopped by aspiration of the medium,
washing once with ice-cold PBS and addition of lysis
buffer: 50-mM Tris/HCl pH 7.5, 1% (wvj1) Nonident
NP-40, 120-mM NaCl, 25-mM NaF, 40-mM b-glycerol
phosphate, 0.1-mM Na3VO4, 1-mM phenyl methyl sulfo-
nyl fluoride (PMSF), 1-mM benzamidine. Cell extracts were
then centrifuged 12,000 g for 30 min at 4 -C and super-
natants were transferred to new tubes. Protein concentra-
tion was measured by Bradford method [24]. Then samples
were mixed with 4 times concentrated Leammli sam-
ple buffer: 200-mM Tris/HCl pH 6.8, 2% (wvj1) SDS,
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0.4% (wvj1) bromophenol blue, 40% (vvj1) glycerol and
2% (vvj1) 2-mercaptoethanol. After boiling for 5 min, cell
lysates were analysed by SDS-PAGE on 10% (wvj1)
polyacrylamide gel. Proteins were blotted onto a nitrocel-
lulose membrane (Hybond-ECL, Amersham Pharmacia
Biotech). Immunodetection was performed according to
the manufacturer’s instructions using rabbit antibodies
raised against phosphorylated p44 (ERK1) and p42
(ERK2) (Cell Signalling Technology). Primary antibodies
were detected with a horseradish peroxidase conjugated
mouse anti-rabbit antibody, and visualized by enhanced
chemiluminescence (ECL, Amersham Pharmacia Biotech).
Equal amount of protein loaded was detected with anti-
actin antibody (Sigma Chemical Co).
Detection of P2Y receptors mRNA and RT-PCR analysis
Total RNA was extracted using TRI reagent. Reverse tran-
scription of total RNA was performed using Expand RT
enzyme. Specific primers for PCR reaction were designed
using FDNA Star_ software (DNA Star Inc., USA). All
primers were based on unique sequences comprising bases
in case of: P2Y1: (1100Y1123) 50 GTG GCG TGG TGT
ACC CTC TCA AGT 30 (forward), (1666Y1650) 50 TGG
TGG CTC GGG ACA GT 30 (backward), product length
566 bp (Acc. No. NM_008772); P2Y2: (229Y250) 50 GCT
GCC GGT GCG CTG ATG AAC T 30 (forward),
(759Y736) 50 CAC CCC GGG CGT AGT AAT AAA
CCA 30 (backward), product length 530 bp (Acc. No.
NM_008773); P2Y4: (549Y572) 50 TGC CCA CCC TCG
TCT ACT ACT ATG 30 (forward), (1016Y993) 50 GAG
AAC GGA GCC GAG AAG ATG ACT 30 (backward),
product length 468 bp (Acc. No. NM_02062); P2Y6:
(161Y177) 50 CCC GCC GGA CCC TGA CC 30 (forward),
(652Y633) 50 GGC GGG CCA TGC GAC AGT AG 30
(backward), product length 491 bp (Acc. No. AF298899);
P2Y12: (342Y362) 50 50CTT TGC TGG GCT CAT CAC
GAA 30 (forward), (744Y721) 50 CTT ATC TTT TGG CCT
CCT GTT GGT 30 (backward), product length 401 bp
(Acc. No. NM_027571). As a reference control glycerol
3-phosphate dehydrogenase (GAPDH) was used. The esti-
mated product length was 900 bp, unique sequence:
(581Y600) 50 ACC ACA GTC CAT GCC ATC AC 30
(forward), (1032Y1013) 50 TCC ACC ACC CTG TTG CTG
TA 30 (backward) (Acc. No. BC083149). Equal amounts of
cDNA were used in parallel experiments. A hot-start PCR
protocol was used, involving denaturation at 95 -C, an-
nealing at 57.8 -C (P2Y1, 32 cycles), at 61.6 -C (P2Y2, 34
cycles), at 59.0 -C (P2Y4, 33 cycles), at 60.6 -C (P2Y6, 34
cycles), at 54.9 -C (P2Y12, 32 cycles), at 65.0 -C (GAPDH,
32 cycles). PCR products were separated on 1% agarose
gel, stained with ethidium bromide and quantified using
ImageQuant and MS Excel software.
Detection of P2X receptors mRNA and RT-PCR analysis
Total RNA was extracted using TRI reagent. Reverse
transcription of total RNA was performed using M-MLV
Reverse Transcriptase. Specific primers for PCR reaction
were designed using FPrimer 3_ software. All primers were
based on unique sequences comprising bases in case of:
P2X1: (927Y946) 5
0 TGG TTG GTA TCA CCA TCG AC
30 (forward), (1009Y1028) 50 CAG GTT CTT CTC CCC
GTA CA 30 (backward), product length 101 bp (Acc. No.
NM_153400); P2X2: (898Y917) 50 CAA CAT TGC AAG
CCA GAA GA 30 (forward), (1012Y1032) 50 TTG TGT
GCC AGT TCT GTG AAG 30 (backward), product length
135 bp (Acc. No. NM_153400); P2X3: (762Y781) 50 CCT
TCC TAA CCT CAC CGA CA 30 (forward), (854Y873) 50
TCC TGC CCA GCA AAC TTA AC 30 (backward),
product length 111 bp (Acc. No. NM_145526); P2X4:
(97Y116) 50 GGC TTT CCT GTT CGA GTA CG 30
(forward), (186Y205) 50 CCA ATG ACG TAA GCC AGG
AT 30 (backward), product length 108 bp (Ac. No. NM_
011026); P2X5: (210Y233) 50 ATG GGT GTT TCT GAT
AAA GAA GAG 30 (forward), (338Y360) 50 TGA GAC
GGA ATG ACA AAG TCT G 30 (backward), product
length 150 bp (Ac. No. NM_033321); P2X6: (213Y232) 5
0
GAC TTG GCC CCT CAG ACT TC 30 (forward),
(297Y316) TTC ACA AAG TCA GCC ACG TC 30 (back-
ward), product length 104 bp (Acc. No. NM_011028);
P2X7: (127Y146) 50 TTT GCT TTG GTG AGC GAT AA0
(forward), (247Y267) GGG AAG GTG TAG TCT GCA
GTG 30 (backward), product length 161 bp (Acc. No. NM_
011027); As a reference control glycerol 3-phosphate
dehydrogenase (GAPDH) was used. The estimated product
length was 900 bp, unique sequence: (581Y600) 50 ACC
ACA GTC CAT GCC ATC AC 30 (forward), (1032Y1013)
50 TCC ACC ACC CTG TTG CTG TA 30 (backward) (Acc.
No. BC083149). Equal amounts of cDNA were used in
parallel experiments. A hot-start PCR protocol was used,
involving denaturation at 95 -C, annealing at 60 -C (30
cycles), at 65.0 -C (GAPDH, 32 cycles). PCR products
were separated on 2% agarose gel, stained with ethidium
bromide.
Results
C2C12 myoblasts, a mouse satellite cell line, were dif-
ferentiated to myotubes by transferring the cells from
high (10% FCS) to low (2% HS) serum growth medium.
The alterations in the morphology of myoblasts, differ-
entiated to myotubes 7 days after changing the serum
growth medium is presented in Figure 1 (Figures 1A and B,
respectively).
In order to find out whether the differentiation of C2C12
cells may have an impact on the mRNA expression of P2Y
and P2X receptors, the mRNA level of these receptors was
measured using RT-PCR method. As a quantitative control
mRNA of constitutively active GAPDH gen product was
used. Figure 1 shows that all, P2Y1, P2Y2, P2Y4, P2Y6 and
P2Y12 as well as P2X4, P2X5 and P2X7 receptors mRNA
were expressed in both myoblasts and myotubes. In myo-
blasts, the mRNA expression of P2Y1, P2Y2 and P2Y4
receptors was strong, while P2Y6 and P2Y12 weak, and the
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Figure 2. Time-dependent activation of p44/42 ERK1/ERK2. C2C12 myoblasts were grown as described in Materials and methods. The cells were
stimulated with specific purinergic receptor ligands (see legend) and ERK activation was measured by immunoblotting (lower panel ) and quantified by
densitometry (upper panel ). Note, that ERK2 phosphorylation level is generally higher, while ERK1 phosphorylation shows stronger dynamics. Actin
was used as a control. Experiments were conducted on three separate occasions. All measurements were made in three repetitions; error bars on the plot
represent TS.D. Concentration of used ligands: ATP 100 mM, ADP 10 mM, 2MeS ADP 10 mM, UTP 100 mM and UDP 100 mM.
Figure 1. Seven days of C2C12 cells differentiation leads to changes in morphology from myoblast (A) to myotubes (B) as observed in light
microscopy (DIC Nomarski). Morphological changes are accompanied by changes in P2Y (myoblasts Y C and myotubes Y D) and P2X (myoblasts Y E
and myotubes Y F) mRNA receptors expression. GAPDH measured as constitutively active control. For details, see Materials and methods. Experiments
were repeated four times.
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strongest mRNA expression was found for P2Y2 receptor
(Figure 1C). However, after myoblasts differentiation to
myotubes, P2Y1 and P2Y12 (ADP sensitive), P2Y4 (UTP
sensitive) and P2Y6 (UDP sensitive) mRNA expression
was distinctly decreased (Figure 1D). Only the level of the
ATP sensitive, P2Y2 receptor mRNA expression was not
changed (Figure 1C versus D). In C2C12 cells mRNA for
P2X1, P2X3 and P2X6 receptors was not present (not
shown). PX4, P2X5 and P2X7 mRNA was found both in
myblasts and myotubes. P2X2 mRNA was absent in
myoblasts and appeared after 7 days of differentiation to
myotubes (Figure 1E versus F).
To determine whether in myoblasts, P2Y receptors are
involved in ERK1/2 activation, the cells were stimulated
with ATP (100 mM), ADP (10 mM), 2MeSADP (10 mM),
UTP (100 mM) and UDP (100 mM), and phosphorylation
status of p44/Erk1 and p42/Erk2 was monitored by
Western blot analysis. As shown in Figure 2, all nucleo-
tides induced a transient increase in the level of p42 and
p44 phosphorylation and in any case p42/ERK2 phosphor-
ylation (also a basal level) was higher than that of p44/
ERK1 (see Western blots). Densitometric analysis of the
blots revealed that, within 5Y15 min, these compounds
induced the highest increase in the phosphorylation level. In
comparison to the basal level, representing ERK1/2 phos-
phorylation in the absence of receptor agonists, changes in
phosphorylation were more pronounced in ERK1 (Figure 2,
left panel). Stimulation of cells with UDP produced the
lowest phosphorylation level of ERKs. In the case of ATP,
an additional peak of ERK1 phosphorylation, after 30 min
of the cells stimulation was also observed (Figure 2, left
panel). The effect of ATP may be explained by the
activation of more than one, different P2 receptors.
To examine whether the effect of nucleotides on p44/p42
ERK1/ERK2 activation was Ca2+ dependent, myoblasts
were placed in calcium-free medium and ERK1/ERK2
activity was measured after 5 min cells treatment with
2MeSADP, UTP and ATP or 15 min with ADP (Figure 3).
As shown, extracellular Ca2+ removal strongly inhibited
ERK1/2 nucleotides activation. These data pointed out the
significant role of Ca2+ in ERK1/2 activation.
In the subsequent experiments influence of ATP on ERKs
activation in C2C12 myotubes was examined. Figure 4A
shows that ATP (100 mM) stimulated a rapid and transient
increase in the phosphorylation level of the active ERK1/
ERK2 in myotubes. Stimulation with ATP reached the
highest increase after 5 min. The second peak of ERK
activation (characteristic for myoblasts) was not observed
and after 30 min, ERK activation returned to the control
level.
Since ATP can activate P2Y2 and P2X receptors, the
cells (myoblasts as well as myotubes) were pretreated 2
min with 100 mM pyridoxal-5-phosphate-6-azophenyl-20,
40-disulfonic acid (PPADS) and then treated for 5 min with
100 mM ATP. PPDS is well known antagonist of P2X2 and
P2X5 receptors, whereas P2X4 and P2Y2 are insensitive to
this compound [14]. Figure 4B shows that preapplication
of PPADS resulted in almost complete inhibition of ERKs
activation in myoblasts, indicating the role of P2X
receptors in this process. On the contrary to myoblasts,
PPADS treatment of myotubes differentiated for 5 or 7
days (time after changing culture medium to differentiating
medium) did not inhibit ATP-induced ERKs activation
Figure 3. Presence of extracellular calcium is required for effective ERK kinase activation. Control shows ERK phosphorylation level in unstimulated
cells. Note that chelation of extracellular calcium by 0.5 mM EGTA in the absence of CaCl2 in medium lowers ERK phosphorylation level slightly
higher than that in control cells. For details, see Materials and methods. Ligand concentrations: ATP 100 mM, ADP 10 mM, 2MeS ADP 10 mM and UTP
100 mM. Experiments were repeated three times.
Figure 4. (A) ATP (100 mM) stimulates ERK I/II kinase phosphorylation
in myotubes. Phosphorylation measurements were made after 0Y60 min of
incubation in ATP solution. (B) Effect of 2 min preincubation with
PPADS (100 mM) on ERK activation in myoblasts by ATP (100 mM),
measured after 5 min of incubation in ligand solution (left). Effect of the
same treatment with PPDS on myotubes: 5 days in differentiating medium
(center) and 7 days in differentiating medium (right). For details, see
Materials and methods. Experiments were repeated three times.
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(Figure 4B). Figure 4B data are results of three indepen-
dent experiments and the level of control ERK phosphor-
ylation are uncomparable between experimental setups.
The effect of ATP on intracellular Ca2+ mobilization in
C2C12 myoblasts and myotubes is shown in Figure 5.
Myoblasts were placed in the medium containing 2-mM
CaCl2 (Figure 5A) or in Ca
2+-free medium (Figure 5B).
Figure 5A (solid line) shows that 100-mM ATP-induced
Ca2+ elevation started only with an initial peak response. In
the presence of PPADS (100 mM) (Figure 5A, dashed line),
Figure 5. Calcium response of C2C12 myoblasts and myotubes. Plots of [Ca2+]i measured as 340/380 nm induced fluorescence of Fura-2 ratio changes
against time. Each trace in this figure represents the mean ratio value of the Ca2+ response. Data shown for one representative experiment of three
repetitions performed for each setup. (A) Two-minute preincubation with PPADS (100 mM) inhibits myoblast calcium response to ATP (100 mM) as
shown on the plot. Note, that cell calcium response in presence of PPADS (dashed line, mean from nine cells) is not only lowered but also biphasic and
longer than response observed in absence of PPDS (solid line, mean from nine cells). This shape suggests metabotropic nature of response while sharp
response is characteristic for ionotropic phenomena. (B) The simillar, slow Ca2+ response to 100 mM ATP (solid line) observed in myoblasts after
extracellular calcium depletion by 0.5 mM EGTA in absence of CaCl2. The response is now independent from PPADS inhibition (dashed line); both
plots show the mean from nine cells. (C) Myotubes response to ATP is similar to that of myoblasts in absence of extracellular calcium. Responses are
long and relatively weak and there is no difference between presence (dashed line, mean from five cells) and absence of PPADS (solid line, mean from
nine cells). (D) Myoblasts and myotubes response to BzATP (100 mM), P2X7 receptor specific agonist. Myoblasts Y solid line (mean from 16 cells) and
myotubes Y dashed line (mean from four cells). The response to BzATP was so weak that the vertical axis scale on this plot had to be changed.
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the kinetic of ATP-evoked Ca2+ changes differed from
those observed without addition of this compound. In the
presence of PPADS, ATP initiated Ca2+ response much
weaker and biphasic, consistent with the PLC-mediated
Ca2+ release from the endoplasmic reticulum Ca2+ stores
(the first phase of calcium response) and capacitative Ca2+
enter from the extracellular space (the second phase). Such
response is typical for metabotropic-Gq protein coupled
receptors [25Y27]. Furthermore, the intracellular Ca2+
concentration generated by ATP in the presence of PPADS
(Figure 5A, dashed line) was at least three times lower than
that induced by ATP alone (Figure 5A, solid line). In the
absence of extracellular Ca2+, ATP was also able to induce
intracellular Ca2+ mobilization, resulting from the direct
action of inositol 1,4,5-trisphosphate (InsP3) on the en-
doplasmic reticulum stores. Addition of PPADS did not
change this response (Figure 5B). Figure 5C illustrates
C2C12 myotubes Ca2+ response induced by ATP in the
cells pretreated (Figure 5C, dashed line), or not pretreated
(Figure 5C, solid line) with PPADS. As it is shown, ATP,
both in the absence and the presence of PPADS generated
similar elongated Ca2+ response, characteristic to metabo-
tropic receptors and P2X receptors antagonist (PPADS) did
not influence this process (Figure 5C, solid and dashed
lines). ATP-induced Ca2+ response was much weaker in
myotubes than in myoblasts (Figure 5). Moreover, similar
Ca2+ response in myotubes was induced by UTP (data
not shown).
a, b-methylene ATP (100Y600 mM), a P2X1/P2X3 ago-
nist produced no Ca2+ response (data not shown) what is
coherent with the lack of mRNA for these receptors both in
myoblasts and myotubes. Figure 5D shows the effect of
100-mM 30-0(4-benzoyl)benzoyl ATP (BzATP) application
on myoblasts and myotubes calcium response. BzATP is a
specific agonist of the P2X7 receptor, which is 10Y100
times more sensitive to this ATP analogue then to ATP
itself [14]. While myoblasts clearly responded to addition
of BzATP, myotubes did not react at all. The presence of
calcium response to BzATP in myoblasts is in agreement
with the presence of P2X7 mRNA in those cells whereas in
myotubes, the P2X7 receptor seemed not to be coupled to
calcium signal. It is worthy adding that response to BzATP
was so weak that we have had to change the vertical axis
scale to show changes, while all other plots on this figure
(Figure 5AYC) have the same scale to make comparison of
responses easier.
Discussion
In this study we investigated the presence of the different
P2Y receptor subunits on the mouse myoblast satellite cell
line, C2C12, and on myoblasts differentiated to myotubes,
7 days after transfer into differentiating medium. Using
RT-PCR we have demonstrated that C2C12 myoblasts did
express a wide range of P2Y receptors Y P2Y1, P2Y2,
P2Y4, P2Y6 and P2Y12. After differentiation to myotubes,
P2Y1, P2Y4, P2Y6 and P2Y12 receptors mRNA expression
distinctly decreased. In contrast, the P2Y2 receptor mRNA
expression was not affected in myotubes. Differentiation
into myotubes did not change the level of P2X4, P2X5 and
P2X7 mRNA expression whereas P2X2 mRNA absent in
myoblasts appears in myotubes.
These results are generally similar to those presented by
Ryten et al. [4], who used primary cultures of satellite
skeletal myoblasts maintained in the medium with 5% HS
to form myotubes. Similarly to our data, the authors
showed the presence of the P2X5 receptor in myoblasts
and myotubes, whereas the P2X2 receptor was absent in
myoblasts and appeared in myotubes only from fifth day of
differentiation. The authors also found that myoblasts
contained the P2Y1 receptor which disappeared after 5
days of differentiation, whereas in our experiments the
level of its expression was only lowered. The difference is
the P2Y4 receptor, which appeared only after plating in
Ryten experiments [4], while in our results was present in
myoblasts and diminished in myotubes. At all these time
points, the P2Y2 receptor was not detectable in Ryten data
whereas in our data P2Y2 mRNA both in myoblasts and
myotubes was always the most aboundant one. Moreover,
in C2C12 myotubes, Henning et al. [28, 29] demonstrated
the activity of this metabotropic P2Y2 receptor. Thus, some
discrepancy between our results and the results of Ryten
et al. [4] may be caused by the different origin of the
cultured cells. Nevertheless, both papers demonstrated dy-
namic expression of P2Y and P2X receptors.
ERK1/2 signalling cascade have been implicated in
myoblast proliferation [30, 31]. The present study shows
that the treatment of C2C12 myoblasts with ATP, ADP,
2MeSADP, UTP and UDP caused a rapid and transient
increase in the level of phosphorylated ERK1/2. This pro-
cess was fully Ca2+ dependent. Application of ATP to
myotubes caused also a significant increase in ERK1/2
phosphorylation. Furthermore, the effect of ATP on ERKs
activation in myoblasts may be inhibited by preaplication
of PPADS, known as an antagonist of P2X2 and P2X5
receptors but not P2X4 and P2Y2 receptors [14, 16, 19, 32].
Such effect of PPADs was not observed in myotubes.
Hence, these results suggest that although the P2Y2 recep-
tor is expressed in C2C12 myoblast cells, P2X5 receptors is
primarily responsible for the observed ATP effects since
P2X2 is absent in myoblasts. On the other hand the myo-
tubes are not PPDS sensitive even though both P2X2 and
P2X5 receptor mRNA is present in those cells. Since ERK
1/2 activation is strongly dependent on Ca2+, these results
could suggest that in myotubes P2X receptors might be
permeable to some other than Ca2+ cations [33].
These conclusions are strongly supported by the differ-
ence in the kinetic of ATP-evoked Ca2+ responses exam-
ined in C2C12 myoblasts in the presence and absence of
PPADS, or extracellular Ca2+. In the presence of extracel-
lular Ca2+ and absence of PPADS, the high and rapid Ca2+
response was most probably generated by P2X receptors,
particularly by the P2X5 receptor. In general, the Ca
2+ in-
flux generated by ligand-gated ionotropic receptors is much
quicker than that mediated by metabotropic-Gq protein
coupled receptors [34]. In addition, the rapid increase in
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intracellular Ca2+ concentration can inhibit InsP3 receptor
and stops the metabotropic receptor action [35, 36]. Thus,
one can expect that when ATP stimulates a cell that
contains P2X and P2Y receptors, a P2X, no P2Y receptor
will be primarily involved in Ca2+ mobilization. On the
other hand, when P2X receptors are antagonized with
PPADS, or when the cells are examined in the absence of
extracellular Ca2+, then the P2Y2 receptor activity may still
lead to the increase in the intracellular Ca2+ concentration.
Such ATP-induced Ca2+ response difference has been ob-
served herein.
In C2C12 myotubes, ATP generated similar, however
very weak Ca2+ response in the presence and absence of
PPADS, and PPADS did not reduced ATP-induced ERKs
activation. These results suggest the lack of P2X receptor
activity in these cells. Similarly, in developing chick skele-
tal muscle, P2X5 and P2X6 receptors were only expressed
at early stages of skeletal muscle development. Their
expression disappeared immediately before the stage at
which fusion of myoblast to form myotubes occurred [11].
Furthermore, as we have already mentioned, in C2C12
myotubes, Henning et al. [28, 29] demonstrated the pre-
sence of the metabotropic P2Y2 receptor, responding to
ATP and UTP and causing a biphasic rise in intracellular
Ca2+ concentration by the release of Ca2+ from the internal
stores and activation of Ca2+ entry from the extracellular
space.
Thus, it seems that during C2C12 myoblast developing,
P2X receptors are the first to be expressed and first to be
down regulated. While in C2C12 myoblasts an ATP-
sensitive P2X5 receptor is primarily responsible for Ca
2+
mobilization and ERK1/2 activation, in myotubes this role
may play the P2Y2 receptor, which mRNA is still
expressed in myotubes. Our data agree with thesis that
P2X5 receptor plays the crucial role in regulation of shift
between myoblast proliferation and differentiation [4, 5].
However, we should be aware that C2C12 cell line never
completely differentiates. Therefore P2Y receptors may be
still active in those cells while in primary lines they do
disappeared during further differentiation into myofibers
[22]. It is also worth adding that we have recently shown
that serum withdrawal for 48 h had effects on glioma C6
cells morphology, which changed from fibroblast-like to
astrocyte-like appearance. Simultaneously with this differ-
entiation-like process, the P2Y1 mRNA expression strongly
decreased and the P2Y12 mRNA slightly increased [32,
37]. Hence, we do believe that changing pattern of
expression and activity of purinergic receptors may be
involved in cell differentiation control and should be
further studied in various cell types.
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